Please login to the form below

Not currently logged in
Email:
Password:

Crestor patent legal battle looms

AstraZeneca is preparing for the start of a legal battle to protect the patent on Crestor.
AstraZeneca will go to court next week to lay out a case against generic challengers, which want to start making cheap copies of the cholesterol-lowering product as early as the middle of next year.

Crestor, which is seen as AstraZeneca's big hope for the next five years, generated sales of $3.6bn (£2.2bn) last year. Analysts think this will rise to $6.7bn by 2014, making it an important revenue earner. The main patent covering the drug's chemical formula is due to run out in the US in 2016.

The launch of a generic alternative would wipe out about a quarter of Crestor's total market value. Precedent, however, is on AstraZeneca's side as similar cases involving Seroquel and Nexium, two of its other key products, were settled in its favour last year.

9th November 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics